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ABSTRACT 
Hepatitis E (HE) occurs predominantly in tropical and semi- 
tropical countries in the form of sporadic cases or epidemics 
of variable magnitude. In industrialized countries, only imported 
sporadic cases of HE have been reported, with little evidence 
of human-to-human transmission. HE resembles hepatitis A 
clinically and epidemiologically but affects young adults rather 
than children, showing a higher mortality rate in pregnant 
women. HE virus (HEV) shares many characteristics of the cali- 
civiruses, although it is genomically distinct from this family of 
viruses. 
New diagnostic tests have been developed, based on the use 
of recombinant or synthetic antigens that are analogues of HEV 
structural proteins. These have been applied to determine the 
prevalence of antibodies (anti-HEV) in various epidemic and 
nonepidemic settings. The prevalence of anti-HEV antibodies 
was unexpectedly low even in endemic areas. A low but con- 
stant rate of seropositivity was observed among normal indi- 
viduals permanently living in nonendemic countries of Europe 
and North America, while an elevated rate of anti-HEV was 
found in certain groups of patients and risk groups. This situ- 
ation as well as other unresolved problems, such as the pos- 
sible involvement of nonhuman reservoirs, the existence of 
subclinical forms, and potential prevention strategies, need fur- 
ther investigation. 
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Type E viral hepatitis, formerly known as enterically trans- 
mitted non-A, non-B hepatitis, is an acute, icteric, self-lim- 
ited disease widely spread in many tropical and 
semitropical countries. In industrialized countries with 
moderate climates, only occasional imported cases of this 
disease are reported. 
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Hepatitis E (HE) is sometimes described as a new 
disease.l The disease may have been recently described 
or identified, but it is not a newly emerging infectious 
disease. It is likely that HE was a disease of antiquity sub- 
sumed within the common term “infectious jaundice.” 
HISTORICAL BACKGROUND 
As far back as the Middle Ages, when hygienic conditions 
for the vast majority of humanity were poor, many enteric 
viral and nonviral infections were constantly present in 
communities. By analogy with modern epidemic situa- 
tions, it could be expected that human populations were 
virtually 100% immune to hepatitis A virus @IA-V) from 
early childhood. Hence widespread epidemics of jaundice 
disease that are noted in historical records most probably 
were associated with hepatitis E virus (IIEV) rather than 
with HAV, particularly if high attack rates among adults, a 
distinctive feature of HE, are taken into account. 
In the 11 th through the 13th centuries, several out- 
breaks of severe jaundice occurred among the crusaders 
during their marches to the Middle East. The descriptions 
of the clinical manifestations of these epidemics resem- 
ble those seen with HE.’ At the end of the eighteenth cen- 
tury, a disease similar to HE affected many soldiers and 
officers of Napoleon’s army involved in military cam- 
paigns in Egypt and Syria.3 It was also suggested that HE 
may have caused the epidemics of so-called “catarrhal 
jaundice,” which were common in Europe and elsewhere 
before the turn of the last century, but became restricted 
to less developed countries later (a pattern that is being 
repeated by hepatitis A now).* In the early 1920s in west- 
ern Ukraine, fatalities in pregnant women, associated with 
acute hepatitis, another distinctive feature of HE, were 
documented among cases of jaundice; in this period, lab- 
oratory methods could only detect bacterial or parasitic 
pathogens, so it was not possible to identify HEV as the 
etiologic agent in these outbreaks.5 
As soon as reliable diagnostic tests for serologic con- 
firmation of hepatitis A and acute hepatitis B had been 
developed, it became evident that large water-borne out- 
breaks and a number of sporadic cases in India and other 
tropical countries were not etiologically associated with 
either I&W or hepatitis B virus (HBV). Several outbreaks 
were thoroughly studied,6-8 and the existence of an 
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enterically transmitted non-A, non-B hepatitis distinct 
from hepatitis A (i.e., representing a separate nosologic 
entity) was strongly suggested. Later this disease was 
designated as hepatitis E (for epidemic, endemic, enter- 
ically transmitted).* 
Virologic studies culminated in identification of a 
viral agent responsible for HE infection and disease; this 
relied on visualization of virus-like particles (VLPs) in the 
excreta of typical HE patients, including an experimentally 
infected human volunteer, and transmission of the dis- 
ease to nonhuman primates.9 For several years, immune 
electron microscopy QEM) remained the only diagnostic 
tool for confirmation of etiologic involvement of HEV. 
Although the IEM was a rather tedious and time-con- 
suming procedure, it permitted more accurate estimation 
of the number of HE outbreaks in endemic areas.lO-l’ 
In 1990, the HEV genome was successfully cloned in 
a prokaryotic system.l* Shortly after, a variety of HEV-spe- 
cific antigens in the form of recombinant proteins and 
synthetic peptides were produced. These antigens could 
be used in conventional enzyme immunoassays (EIAs) as 
an immobilized reagent, making the test itself suitable for 
efficient large-scale serologic surveys.15 
THE VIRUS 
The etiologic agent of HE is a small, spherical, nonen- 
veloped virus. In IEM, the HEV particles (virions) look 
like round objects 27 to 34 nm in diameter often coated 
with a “halo” of attached antibody molecules. When the 
concentration of antibody is not too high, cup-shaped 
indentations on the virion surface and spikes on its con- 
tour can easily be seen, providing an argument for simi- 
larity between the HEV and the viruses found in the 
Caliciviridae family Other characteristics of HEV also com- 
patible with those of caliciviruses are shown in Table 
1 .16J7J7a It was repeatedly noted that HEV virions are not 
stable and lose their integrity after routine laboratory pro- 
cedures, such as freeze-thawing, sedimentation in salt solu- 
tions, and dialysis. l8 This feature is rather unusual for an 
agent which, under natural conditions, survives in the 
environment despite exposure to many unfavorable con- 
ditions, such as elevated temperature, solar radiation, and 
osmotic extremes. 
The HEV exists as a single serotype; that is, the HEV 
isolates from different geographic regions share the same 
conservative antigenic pattern. In usual serologic tests, 
the HEV particles and HEV-specific recombinant antigens 
react equally well with sera from convalescent patients 
irrespective of geographic origin of either viruses or sera. 
Furthermore, monkeys infected with one HEV isolate 
acquire resistance to superinfection with the HEVs from 
distinct outbreaks.19 
Based on molecular cloning experiments, the HEV 
genome is a single-stranded positive-sense RNA of approx- 
imately 7.5 kb polyadenylated at 3’ terminus.20 The 
genome is flanked with short noncoding sequences at 
S’and 3’ termini and encompasses three partially over- 
lapping open reading frames (ORFs). The larger one 
(ORFl), of approximately 5.0 kb, is located at the 5’ end, 
and it encodes for nonstructural elements with enzymatic 
activities. The second largest (ORFZ), of 2.0 kb, at 3’ end 
controls the synthesis of major structural protein(s). The 
smallest ORF3, with 0.3 kb, occupies the intermediate 
position and expresses a protein of unknown function 
(Figure 1). It is assumed, although not yet proven, that 
the messages for nonstructural and structural proteins of 
HEV are generated separately through a hypothetic mech- 
anism of transcription regulation.‘l Comparison of 
nucleotide sequences in a genome fragment encoding 
for putative RNA-directed RNA polymerase (RDRP) 
revealed 87 to 94% homology between the Asian strains 
of HEV, and as low as 77% homology between the strains 
from different continents (e.g., Burmese versus Mexican 
Table 1. Comparative Characteristics of Hepatitis E  Virus and Some Caliciviruses 
HEY Caliciviruses’6,‘7 
Virion morphology 
Size (diameter) (nm) 27-34 32-38 
Surface indentations Dim Sharp 
Flotation properties 
S  
B?!Eya’yant density, g/cm3 
183 170-l 85 
CSCI 1.35 1.33-I .39 
KTar/gly 1.29 
Stability 
In lab conditions Labile Labile 
In the evenironment Stable Stable 
Virion composition 
RNA Single-stranded positive sense -7.5 kb Single-stranded positive sense -8.2 kb 
Maor protein 55-70 kDa 60-71 kDa 
Antigenic pattern Single serotype Several distinct serotypes (specific to host species) with considerable 
cross-reactivity 
Host range Humans, non-human primates; other Interspecies transmission is not infrequent; potential for zoonosis 
vertebrates 
Adapted from Balayan, 1 994.‘7a 
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Figure 1. Schematic representation of hepatitis E virus genome. 
ORFl : Nonstructural proteins: M  = methyltransferase; Y = domain V; 
Pr = papain-like cysteine protease; P = proline “hinge;” X = domain X; 
H = helicase; R = RNA replicase. ORF2: Structural protein(s). ORF3: 
A protein of unknown function. - = Noncoding sequences, 
isolates).22 Such genetic divergence does not go beyond 
the strain variations normally observed within the mem- 
bers of a single virus genus. 
The HEV shares many common morphologic and 
physicochemical characteristics of caliciviruses. However, 
the nucleotide sequences of the HEV genome fragment 
corresponding to RDRP was not homologous to any 
entries in the GenBank database,l* including those of the 
prototype calicivirus strains, and no similarities were 
found between the HEV and caliciviruses in genome com- 
position, although their overall genomic organization 
seems to be the same.z1 A distant degree of sequence 
homology was seen with rubella virus belonging to the 
Rubivirus genus within the togavirus family and scarcely 
studied plant furoviruses. Although the final taxonomic 
definition of the HEV remains to be established, it can 
be tentatively assumed that this virus is a single member 
of a novel virus genus that may be further placed in either 
calici- or togavirus families or perhaps will represent a dis 
tinct virus family. 
LABORATORY MODELS 
Over ten species of nonhuman primates appeared to be 
susceptible to experimental HEV infection, showing some 
features similar to those of the human disease. Wild- 
caught cynomolgus macaques were predominantly used 
in the experiments, though rhesus monkeys, African 
vervet monkeys, marmosets, tamarins, and chimpanzees 
were also effectively inoculated. It was shown recently 
that Old World monkeys, trapped in their natural habitat, 
occasionally have antibodies to HEV (anti-HEV).23 
There are five criteria according to which the HEV 
infection in these animals can be recognized: 
1. Pathologic elevation in the level of liver enzymes, 
alanine aminotransferase (AL73 and isocitrate dehy- 
drogenase (ICD), temporally related to the infection, 
2. Specific morphologic alterations (necroinflammation) 
in hepatic cells, 
3. Detection of HEV antigen(s) in the liver by a fluo- 
rescent antibody technique (FAT), 
4. Fecal shedding of HEV particles, and 
5. Anti-HEV immune response, particularly persistence 
of class M antibody. 
In addition, a test for HEV RNA in blood (i.e., the 
viremic status, using the polymerase chain reaction [PCR]) 
was applied to monitor the HEV infection more accu- 
rately.24 No jaundice has been observed in HEV-infected 
monkeys or apes. 
The biphasic profile of liver enzyme elevation is char- 
acteristic of experimental HEV infection in nonhuman 
primates (Figure 2). Usually a “minor” peak appears as 
early as 6 to 12 days after inoculation, followed by a week- 
long period of normalization of enzyme levels and then 
by a new, often more pronounced, “major” peak. In the 
interval between these two peaks, the HEV particles are 
regularly visualized in the stool and the viral antigen can 
be detected in liver cells with specific fluorescent anti- 
body. It is hard to say whether this enzyme profile takes 
place in human HE infection too, since the first peak 
obviously corresponds to the preclinical stage when per- 
sons are unlikely to seek medical attention.25,26 
Experimentation in nonhuman primates provided a 
valuable source of HEV in the form of relatively pure sus- 
pensions of viral particles in the bile derived directly 
from the gall bladder of infected monkeys (e.g., this mate- 
rial was used for molecular cloning of HEV).‘* Pedigreed 
serum panels composed of pre-inoculation, acute, and 
convalescent sera were also obtained from infected mon- 
keys and further employed for the validation of serologic 
assays and immunoscreening of cDNA libraries.z2 
The HEV does not grow well in conventional cell 
culture systems. Attempts to isolate the virus from 
patients’ excreta by inoculation and passages in a variety 
of cell cultures has been unsuccessful. However, under 
certain experimental conditions, HEV appears to be capa- 
ble of propagating in cultivated cells. In our previous stud- 
ies, this was achieved by co-cultivation of primary liver 
Figure 2. Typical time-course of HE!V infection in monkeys (cynomol- 
gus macaques). ALT = alanine aminotransferase; FAT = fluorescent 
antibody technique; VLPs = virus-like particles. 
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and kidney cells derived from HEV-infected monkeys at 
the peak of disease, with fresh cells of continuous lines 
(FRhK-4 and 4647). The persistent infection was soon 
established and further maintained in serial passages; the 
presence of HEV in these systems could be determined 
by cDNA hybridization, fluorescent antibody technique 
(FAT), and inoculation of persistently infected cells into 
susceptible monkeys.” Later the HEV RNA in persistently 
infected cells also was detected by a PCR technique 
(unpublished results). The Chinese isolates of HEV were 
shown to grow in selective cell lines producing the 
marked cytopathogenic effect; no additional adaptation of 
HEV was required for the efficient propagation of the 
virus in these cells.28,29 
Evidence is accumulating that, in addition to pri- 
mates, nonprimate vertebrates also may be susceptible 
to HEV infection. In 1990, it was shown that HE can be 
reproduced in young (sub-adult) domestic pigs after intra- 
venous inoculation with human HEV isolates.30 The time- 
course and other parameters of experimental infection in 
these animals were similar to those observed in mon- 
keys; some infected pigs even developed jaundice, man- 
ifested as icteric skin and sclera at weeks 3 to 4 after 
inoculation. This finding was confirmed by the detection 
of HEV RNA sequences and anti-HEV antibody in stool 
and serum specimens, respectively, collected from free- 
roaming swine in the Kathmandu Valley of Nepal.31 
Among other domestic animal species, lambs were found 
to be susceptible to HEV infection, at least under exper- 
imental conditions.32 
Hepatitis E virus also has been transmitted to labo- 
ratory rats.33,34 Although no clinical disease was observed 
in these animals, evidence for virus replication in liver 
and nonliver (spleen, lymph nodes, small intestine) cells 
as well as pathologic alterations (signs of necroinflam- 
mation) in liver tissue was obtained. From the epidemi- 
ologic point of view, it is noteworthy that HEV infection 
can occur in wild rodents as well. In one study, anti-HEV 
antibody was detected in some wild-trapped rodents liv- 
ing in close proximity to potable water sources in a rural 
area endemic for HE.33 All these findings imply possible 
involvement of domestic and perhaps certain wild ani- 
mals in the perpetuation of HEV This has not been thor- 
oughly investigated, and whether HE is a zoonosis remains 
to be determined. 
CLINICAL COURSE 
Clinical aspects of HEV infection have been extensively 
reviewed.4Js,35 Hepatitis E resembles hepatitis A as well as 
other forms of acute viral hepatitis, although some hepa- 
tologists claim that they can differentiate HE on the basis 
of minor symptoms and clinical biochemical findings. 
Pi” Nauaaa Fever Prurltls 
The liver seems to be the only target organ for HEV Figure 3. Clinical symptoms in adult patients with hepatitis E. Mod- 
infection, hence extrahepatic manifestations of the disease ified from Purcell and TicehursL4 with permission. 
are rare. The incubation period ranges from 15 to 40 days, 
with a median of 35 days being more protracted than 
that observed with hepatitis A. The onset of symptoms 
is usually abrupt; practically all the signs and symptoms 
of the disease appear simultaneously. Normalization 
occurs within 2 to 3 weeks, except for severe fulminant 
cases. The disease is usually self-limited with no chronic 
sequelae; however, the elevated levels of liver enzymes 
(e.g., AU) sometimes can persist for an additional 1 to 2 
weeks. 
Histopathologic studies of liver tissue obtained by a 
needle biopsy provide no pathognomonic features for 
HE, simply yielding results consistent with acute viral 
hepatitis, often with abundant cholestasis. 
The main clinical symptoms of HE in the order of 
frequency of occurrence are shown in Figure 3. When the 
disease progresses toward the severe fulminant forms, 
which occurs at a rate of l-3% in adults and up to 20 to 
30% in pregnant women, the symptoms of increasing 
intoxication due to liver dysfunction begin to dominate 
the clinical picture. In pregnant women this status fre- 
quently leads to abortion or premature delivery, which in 
turn aggravates the disease. 
Asymptomatic or subclinical forms of HE are not well 
defined. Recently, it became possible to identify HEV 
infection by detecting anti-HEVs of IgG and IgM class 
capable of reacting with recombinant or synthetic HEV 
antigens. In suspected HE cases, the rate of anti-HEV 
seropositivity varied significantly, depending on the com- 
position of HEV-specific antigens, the geographic regions 
where the cases occurred, and the class of antibody that 
was detected.36 
GEOGRAPHIC SPREAD AND EPIDEMIOLOGY 
In the past, when HE was recognized only by the appear- 
ance of distinct water-borne epidemics or constant 
Frequency (%) 
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Table 2. Main Epidemiologic Features 
of Hepatitis E  Virus Infection 
1. Fecal-oral mode of transmission 
2. Frequent occurrence of epidemics and outbreaks associated with 
consumption of sewage-polluted water 
3. Geographic distribution: tropical and subtropical countries 
throughout the world 
4. Seasonal pattern: increased incidence during or after rainy 
seasons, in Southeast Asia; during late autumn, in Central Asia 
(Confederation of Independent States and China) 
5. Age-specific prevalence: highest attack rate in young and middle- 
aged adults (15-40 y) 
6. Higher incidence of infection in adult males versus females; no sex 
preponderance in children 
7. Limited spread of infection around source case in households, 
communities, or hospitals (low secondary attack rate) 
presence of typical sporadic cases, the area of HE distri- 
bution included many developing countries located in 
the tropical belt. In addition, large foci of the disease were 
found to exist in the Central Asia republics (territory of 
the former USSR) as well as in northern and central 
provinces of China. Among the countries that reported 
the occurrence of HE were India, Pakistan, Nepal, Myan- 
mar (formerly Burma), Indonesia, China, Ethiopia, Sudan, 
Somalia, Algeria, Senegal, Ivory Coast, and Mexico. These 
countries share poor socioeconomic and hygienic con- 
ditions that facilitate the spread of HEV through conta- 
minated water and, perhaps, household contacts. It should 
be noted, however, that the above picture was obtained 
on the basis of available information from the public 
health sources and laboratory investigation of clinical 
specimens; hence, a significant portion of HE morbidity 
obviously remained under-reported. 
The application of serologic tests with recombinant 
or synthetic HEV-specific antigens has revealed the pres- 
ence of anti-HEV in human populations practically in 
every country in which a proper survey has been per- 
formed, including the industrialized countries where clin- 
ically overt HE occurs only as imported sporadic cases. 
It is further discussed below whether these fmdings are 
compatible with the real distribution of HEV infection. 
The main epidemiologic features of HE are summa- 
rized in Table 2. These features focus on endemic areas, 
without taking into account the rare but constant pres- 
ence of anti-HEV seropositivity in the rest of the world. 
Table 3 compares the characteristics that usually are used 
to describe the endemic versus nonendemic areas. 
SEROLOGIC SURVEYS 
In 1992, an enzyme immunoassay (EIA) based on the use 
of recombinant antigens, analogues of the HEV structural 
proteins, was introduced.15 A variety of EIA variants were 
recommended thereafter; they differed with regard to the 
nature and composition of HEV-specific antigens ulti- 
mately aimed at the maximal detection of anti-HEV in 
patients and healthy subjects. At present, there are three 
groups of antigens included in the EIA: (1) recombinant 
proteins expressed in Escherichia co&l5 (2) recombinant 
proteins expressed in insect cells3’ and (3) combinations 
of synthetic peptides linked to a large-molecule carrier.38 
None of the tests developed to date contain native whole- 
virion HEV antigens. 
The antigen most commonly used consists of a 327 
amino acid fragment from the 3’ terminus of ORF2, pre- 
sumably a component of an HEV structural protein, and 
a sequence of 123 amino acids representing the full 
length of ORF3; both are derived from the Burmese strain 
of HEV and are expressed in E. coli. It is included in a 
commercially available test kit as a solid-phase reagent. 
Anti-HEV antibody, detected with this reagent, was found 
to be present in a significant portion of suspected HE 
patients.39x40 
Irrespective of the test employed, anti-HEV was 
detected in normal healthy individuals who were per- 
manent residents of areas endemic for HE; however, the 
rate of anti-HEV seropositivity was low and never reached 
the figures regularly observed for the antibody to HAV, an 
etiologic agent of another enterically transmitted viral 
hepatitis. 4o-42 For example, in the hyperendemic area of 
Tadjikistan, 8.5% of healthy subjects were seropositive 
for anti-HEV38 The rates for anti-HEV seropositivity were 
4 to 5% in India,43 2.8% in Thailand,43 and 20.2% in 
China.44 In our previous studies of sera collected from 
healthy subjects and nonhepatitis patients in another 
Table 3. Hepatitis E: Characteristics of Endemic Versus Nonendemic Areas 
Endemic Nonendemic 
Incidence of HE High 
Epidemiologic manifestations 
Low (or none) 
Outbreaks of variable magnitude 
General sanitation 
Only imported sporadic cases 
Poor 
Spread through contaminated water sources 
Adequate 
Frequent Absent 
Personal hygienic habits Only in certain social groups 
Nonhuman HEV reservoirs 
In great majority of population 
Very probable If exist, do not play essential role 
HE reporting system Often under-reported 
Climatic conditions 
Registered all suspected cases 
Hot climate Moderate climate 
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hyperendemic area (Kirghizstan), anti-HEV seroprevalence 
was 4.6%, whereas anti-WV seroprevalence was 93.0%.*5 
The paucity of anti-HEV seropositives in normal 
human populations of endemic countries remains unex- 
plained. One could speculate that (1) anti-HEV antibody 
does not persist for a long period and falls below 
detectable levels soon after the acute infection, (2) the 
HEV causes predominantly a clinically overt disease and 
sub-clinical or “silent” forms rarely occur-this would be 
atypical for an enterically transmitted infection, or (3) the 
serologic tests miss a significant portion of the spectrum 
of anti-HEV antibodies. 
Unexpectedly, a low rate of anti-HEV was also found 
in the nonendemic industrialized countries located mainly 
in the moderate climate belts; as a general tendency this 
rate increases in the north to south direction. In the 
Netherlands, 1.1% of blood donors appear to be anti-HEV 
sero-positive,46 in the United Kingdom, 1 .O%,” in France, 
0.9%*’ (in French pregnant women, 2.6%*“), in Spain, 
2.2%,*’ in Israel, 2.6%,49 in Switzerland, 4.5%,50 to mention 
only a few of these examples. In a nonendemic area of 
Russia (Moscow) only one (0.6%) of 165 observees was 
anti-HEV seropositive whereas 43.7% were seropositive 
to HAV45 Among blood donors in the United States, 2.1% 
had anti-HEV antibodies,15 a prevalence that is ten times 
higher than that for hepatits C virus.51 
An increased rate of anti-HEV seropositivity was 
demonstrated in certain groups of patients with liver 
pathologies that, according to present knowledge, are not 
directly associated with the HEV infection, such as 
chronic autoimmune liver disease,52 chronic hepatitis, 
and primary liver cancer. j3 Anti-HEV seropositives were 
found among hemophiliacs, 54 donors rejected from blood 
donations due to elevated levels of ALT,,‘x~~ and HIV- 
infected homosexual men,5j more often than in the gen- 
eral population. 
There are three hypothetical, though not mutually 
exclusive explanations for these phenomena: (1) the inad- 
equacy of methods employed for the detection of anti- 
Hn/: (2) a situation where the same virus causes a certain 
pathology in one climatic zone and a completely differ- 
ent disease in another (e.g., the Epstein-Barr herpesvirus 
is the cause of infectious mononucleosis in moderate cli- 
mates and Burkitt’s lymphoma in the sub-Saharan Africa), 
or (3) the existence of an unrecognized agent capable 
of cross-reacting with antibodies to HEX 
CONTROL AND PREVENTION 
Improvement of hygienic standards and general sanita- 
tion in endemic areas could result in decreasing HE mor- 
bidity. In particular, measures to prevent contamination of 
water sources are expected to be effective; instruction in 
the proper treatment of potable water can be recom- 
mended as well. It is important that pregnant women 
should be admitted to intensive care units as soon as HEV 
infection is suspected. 
There are some prospects for the development of a 
subvirion HEV vaccine from genetically engineered 
immunogens. Preliminary evidence has shown that the 
HEV-ORF2 product expressed in E. coli and fused to trpE 
protein can protect susceptible monkeys from challenge 
with wild-type HEV56 An alternative immunogen, con- 
sisting of full-length ORF2 protein expressed in insect 
cells, has been suggested recently as a suitable candidate 
vaccine for HE (Tsarev SA, personal communication). 
Among the target groups that should be considered 
for vaccination are females of pre-child bearing age in 
endemic areas and persons from nonendemic areas plan- 
ning to visit tropical countries. 
CONCLUSIONS 
Despite the rapid progress in understanding the etiology 
and pathology of HE, many areas require futher research. 
The unusual patterns of anti-HEV seroprevalence stimu- 
late further studies to determine whether the paucity of 
anti-HA7 in endemic areas is associated with a higher sus- 
ceptibility to HEV infection in the majority of the popu- 
lation. The rare, but significant presence of anti-HEV in the 
industrialized countries signals the need for regular vig- 
ilance. Additionally, the possible role of domestic or wild 
animals in HEV transmission should be further elucidated 
before a general strategy for prevention of HE in endemic 
countries can be formulated. 
Information concerning the emergence of a third 
enterically transmitted hepatitis agent is awaiting confir- 
mation.57,js This may further complicate healthcare in 
many countries. However, the rapid growth in the under- 
standing of HEV demonstrates the benefit of collaboration 
among scientists, clinicians, and public health experts. 
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